Navigation Links
Drug Delivery Technologies Show Promise of Improving Clinical Outcomes for Patients at PODD: Partnership Opportunities in Drug Delivery Conference
Date:7/2/2012

NEW YORK, July 2, 2012 /PRNewswire/ -- In an effort to remove barriers and embrace collaborations to get therapeutics to patients faster, pharmaceutical and biotech companies will listen to more than 25 drug delivery technology presentations, ranging from novel delivery devices to formulation technologies at the 2nd Annual PODD: Partnership Opportunities in Drug Delivery conference, October 1-2, 2012, at the Boston Park Plaza hotel in Boston, MA.

The PODD program is designed to introduce emerging and enabling drug delivery technologies to help pharmaceutical and biotech drug formulators obtain better clinical outcomes for patients. The PODD event features keynote addresses by two leading scientists in drug delivery, Dr Robert Langer, the David H. Koch Institute Professor, MIT, and Dr. Stephen Oesterle, Senior Vice President for Medicine and Technology, Medtronic.

Dr Barbara Lueckel, Global Business Development Director, Roche returns as the PODD Chairperson. Dr. Lueckel found the inaugural PODD event served as a platform to facilitate innovative collaborations, noting that, "The panels provided an opportunity to gain further insights into companies' thinking on drug delivery partnering and to engage panelists into additional discussions."  She also said, "I am glad we will see more panel discussions in 2012."

Additional industry experts speaking at PODD include:

  • Dr. Sesha Neervannan, Vice President, Pharmaceutical Development, Allergan
  • Dr. Julia Rashba-Step, Senior Director, Novel Delivery Technologies, Pfizer
  • Dr. Anand Subramony, Head of Novel Delivery Technologies & Therapeutics, Novartis
  • Dr. Keith Horspool, Vice President, Pharmaceutical Development, Boehringer Ingelheim

Further highlights of the PODD program include pre-arranged one-on-one partnering meetings, a drug delivery exhibit hall, numerous networking breaks and a reception. Over 250 attendees are anticipated. Companies participating in the 2012 PODD event include Allergan, Aptalis, Becton Dickinson, Boehringer Ingelheim, CIMA Labs, GlaxoSmithKline, Janssen, 3M Drug Delivery Systems, Medtronic, Merck, Novartis, Patheon, Pfizer, Roche and Shire.

For more information, please visit www.theconferenceforum.org or contact Meredith Sands at Msands@theconferenceforum.org or call 646-350-2586.


'/>"/>
SOURCE The Conference Forum
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
2. New Research Available on the Multi-Billion Dollar Transmucosal Drug Delivery and Systemic Nasal Sprays Markets
3. Valeritas Inc. Selects dLifes New Diabetes Patient Engagement Solution For Valeritas V-go Disposable Insulin Delivery Device
4. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
5. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
6. MicroVention Announces First Patient Enrollment In Clinical Trial To Compare Coiling Technologies For Treating Brain Aneurysms
7. Response to U.S. Supreme Courts Healthcare Decision by Michael Zamagias, Chairman, TeleTracking Technologies
8. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
9. Updated: LHA Life Sciences & Medical Technologies Virtual Conference
10. LHA Life Sciences & Medical Technologies Virtual Conference
11. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... it has concluded agreements with the U.S. Department of ... (SEC) to resolve the previously disclosed U.S. Foreign Corrupt ... as in relation to the former deferred prosecution agreement ... with DOJ and SEC, respectively, on March 26, 2012.  ...
(Date:1/12/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical ... findings at this week,s Orlando Dermatology Aesthetic & Clinical (ODAC) ... acnes -induced inflammation. The data will be shared ... Acne Pathogenesis," at ODAC, which is being held Jan. 13-16 ... ...
(Date:1/12/2017)... -- This new report from VPGMarketResearch contains 897 pages, ... German hospital microbiology testing market, including:  ... practice, as well as key economic, regulatory, demographic, social ... next ten years.  ... of major infectious diseases and microorganisms.  ...
Breaking Medicine Technology:
(Date:1/15/2017)... ... January 15, 2017 , ... Going above and ... that strives to better communities around the world by offering the Gensuite team ... the opportunity for team members to become involved in a cause that is ...
(Date:1/15/2017)... CA (PRWEB) , ... January 15, 2017 , ... ... their choice of best physicians in eight Bay Area counties for 2017. Almost ... the healthcare research company managing the award process. Results were announced the magazine’s ...
(Date:1/14/2017)... ... 2017 , ... Healthy living brand Moody Zook recently came ... With more and more people opting to go organic in their lifestyle, the ... to specific needs. , Moody Zook focused particularly on their newly launched activated ...
(Date:1/13/2017)... (PRWEB) , ... January 13, 2017 , ... ... that raise blood sugar levels. Counting carbohydrates is as easy as checking the ... only nutrient that affects blood sugar levels. Despite being sugar-free, proteins can influence ...
(Date:1/13/2017)... ... January 13, 2017 , ... With ... on the challenge of providing additional organic alternatives for customers who have grown ... the brand’s new line of all-natural activated charcoal products, Moody Zook Chief Executive ...
Breaking Medicine News(10 mins):